Open AccessTreatment of Hypertension in the Inpatient Setting: Use of Intravenous Labetalol and Hydralazine
Author(s) -
Weder Alan B.,
Erickson Steven
Publication year - 2010
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1751-7176.2009.00196.x
Subject(s) - labetalol , medicine , hydralazine , blood pressure , anesthesia , pharmacy , intravenous infusions , family medicine
J Clin Hypertens (Greenwich). 2010;12:29–33. © 2009 Wiley Periodicals, Inc. Acute blood pressure elevations are commonly treated in hospitalized patients. There are no guidelines for appropriate practice and no evidence that such treatment is useful. The authors performed a retrospective review of medical and pharmacy records to determine how often intravenous hydralazine and labetalol are ordered and administered. During a 1‐year study period, a total of 29,545 hospitalizations were recorded. The authors identified 2189 patients (7.4% of all patients) for whom 7242 orders were written for hydralazine as needed (10–20 mg per dose) and 5915 for labetalol (10–20 mg per dose). Ordered drugs were adminstered in 60.3% of patients, and the average number of doses administered was 5.3±8.2 (mean ± SD) for hydralazine and 5.6±7.7 for labetalol. Hospital length of stay (LOS) for patients for whom hydralazine was ordered was 12.0±15.9 days for those who received at least 1 dose and 7.1±9.0 days for those who did not receive a dose (P<.001). For patients for whom labetalol was ordered, patients receiving at least 1 dose had an LOS of 11.8±16.1 days vs 7.9±10.4 days for those who did not receive a dose (P<.001). Treatment of elevated blood pressure in in‐patients is a common practice. The authors suggest that evidence is needed to determine whether the practice is of benefit.